Physician profile
Ann Lottes
NPI 1588015424
$2,171.85
in general payments reported to CMS, 2019-2025
25 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.36 · 2020: $49.76 · 2021: $133 · 2022: $573 · 2023: $613 · 2024: $350 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $365.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $337.01 | 2021-2025 | |
| Abbvie INC. | $313.86 | 2022-2024 | |
| Lilly USA, LLC | $246.24 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $108.89 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $98.93 | 2022-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $89.74 | 2021-2023 | Xarelto |
| Abbott Laboratories | $83.49 | 2022-2025 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $83.38 | 2021-2022 | |
| Astellas Pharma US INC | $82.07 | 2019-2024 | Veozah |
| Amgen INC. | $53.80 | 2019-2025 | Evenity, Prolia |
| Almatica Pharma LLC | $45.13 | 2022-2023 | Loreev Xr, Gralise |
| Exact Sciences Corporation | $41.71 | 2023-2025 | Cologuard Collection Kit |
| Phadia US INC. | $33.17 | 2024-2025 | Immunocap |
| Sunovion Pharmaceuticals INC. | $26.99 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.38 | 2025 | Aptima, Third Wave, Thinprep 2000 Processor |
| E.R. Squibb & Sons, L.L.C. | $21.85 | 2025 | Eliquis |
| Sumitomo Pharma America, INC. | $18.89 | 2025 | Gemtesa |
| Neos Therapeutics, LP | $15.51 | 2023 | Adzenys Xr-Odt |
| Amarin Pharma, INC. | $14.68 | 2019 | |
| Sanofi Pasteur INC. | $14.51 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.98 | 2023 | Quviviq |
| Globus Medical, INC. | $13.95 | 2025 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $12.50 | 2020 | |
| Merck Sharp & Dohme LLC | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Lottes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.